casinokid11211, This is how I see the current situation. When I saw the January (3.05 mills) and February (2.8 mills) revenue numbers, I was kind of worried. Those numbers were not quite aligning with the numbers from the Q4 for 2019. Everyone was saying those January and February numbers were record numbers and good. I thought RXMD slowed down at that time. I was wondering how RXMD could make 40 mills this year based on those numbers. I thought things were not working for RXMD despite everyone's excitement. Now it seems RXMD found some venues that can improve their revenues. It takes some time to make everything work smoothly when you make acquisitions. Things may be start happening. They made a good recovery in March. It seems 40 mils is a realistic target now. Their business seems to be thriving in this unusual situation. When I saw RXMD 4 years ago, OS was around 330 mills. I thought the number was relatively low for an OTC company. Now it is around somewhere around 450 mills after a couple of acquisitions and their revenue is 1.7 times of the 2016 revenue. They accomplished it without increasing the OS number 1,7 times. I think RXMD is better positioned today than they were 4 years go. Those 120 mill shares were well spent. I hope they are going to make it to Nasdaq, When they do, they need to have a healthy stream of profits by then. I don't mind to see a RS if they are health enough. If they are not healthy enough, they will be eaten alive even if they can up list to Nasdaq temporarily. I am cautiously optimistic.
